Vaccines - United Arab Emirates

United Arab Emirates

The United Arab Emirates is expected to witness a significant revenue growth in the Vaccines market, projected to reach US$117.70m by 2024.
Furthermore, it is anticipated that the market will exhibit an annual growth rate (CAGR 2024-2029) of 7.43%, resulting in a market volume of US$168.40m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$29,120.00m in 2024.
The United Arab Emirates is investing heavily in research and development of vaccines to strengthen its healthcare system and promote public health.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in United Arab Emirates has been on the rise in recent years.

Customer preferences: The population in United Arab Emirates has become increasingly health-conscious, leading to a higher demand for vaccines. Additionally, the government has been actively promoting vaccination programs, which has further increased the demand.

Trends in the market: One of the major trends in the vaccines market in United Arab Emirates is the increasing demand for flu vaccines. This is due to the high prevalence of flu in the region, especially during the winter months. Another trend is the growing demand for travel vaccines, as more people are travelling abroad for work and leisure.

Local special circumstances: The United Arab Emirates has a large expatriate population, which has contributed to the demand for vaccines. Many expatriates come from countries where certain diseases are more prevalent, and they require vaccines to protect themselves while living in the UAE. Additionally, the UAE is a hub for international travel, which has led to a higher demand for travel vaccines.

Underlying macroeconomic factors: The UAE has a strong economy, which has allowed for increased investment in healthcare infrastructure and services. This has led to better access to vaccines for the population. Additionally, the government has been actively promoting healthcare initiatives, including vaccination programs, which has further contributed to the growth of the vaccines market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.